SCHEMBL31225571

SCHEMBL31225571

CC(=O)OCC(=O)N[C@H]1[C@H]([C@H](OC(C)=O)[C@@H](CN=[N+]=[N-])OC(C)=O)O[C@](Sc2ccc(C)cc2)(C(N)=O)C[C@@H]1OC(C)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31226079 0.94 — —
SCHEMBL31225814 0.87 — —
SCHEMBL31225519 0.86 NEU4 (0.32) —
SCHEMBL31502434 0.86 — —
SCHEMBL24630222 0.83 — —
SCHEMBL24630325 0.83 — —
SCHEMBL31225467 0.82 — —
SCHEMBL27391585 0.82 — —
SCHEMBL31502418 0.81 LMNA (0.31) —
SCHEMBL31225296 0.81 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 — — EP disclosed
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 — — US disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 — — WO disclosed
Send feedback